Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

Annexon (Nasdaq: ANNX) announced that CEO Douglas Love will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET.

Rhea-AI Summary

Annexon (Nasdaq: ANNX) announced that CEO Douglas Love will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET.

A live webcast will be available on the company's Investors "Events & Presentations" page and a replay will be archived on the Annexon website for 30 days after the presentation.

Argus Apr 9 session

+1.49% close to close Open Argus

Details

News Market Reaction – ANNX

On Apr 9, the first trading day after this news, ANNX closed 1.49% above the previous close.

Data tracked by StockTitan Argus for the Apr 9 session.

Market Context

This announcement highlights Annexon’s participation in the Needham healthcare conference, continuin...

Analysis

This announcement highlights Annexon’s participation in the Needham healthcare conference, continuing a pattern of investor outreach that includes prior TD Cowen and KOL events. With late-stage programs and $238.3M in cash supporting runway into the second half of 2027, context from recent earnings and regulatory filings remains more material than this scheduling news. Investors may focus on upcoming ARCHER II Phase 3 data, regulatory milestones, and cash burn metrics when evaluating future developments.

Key Figures

Cash & investments: $238.3M R&D expense: $184.7M G&A expense: $31.7M +5 more

Cash & investments

$238.3M

Cash, cash equivalents and short-term investments at 12/31/2025

R&D expense

$184.7M

Research and development expenses for full-year 2025

G&A expense

$31.7M

General and administrative expenses for 2025

Net loss

$208.5M

Net loss attributable to common stockholders in 2025

Loss per share

$1.34 per share

Net loss per share for 2025

Market cap

$930,751,131

Market capitalization prior to this news

Disease burden

10 million people

Neuroinflammatory diseases targeted, affecting nearly 10 million worldwide

Short interest

10.95%

Reported short interest as a percentage of float

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Earnings update

   24h Move

   +11.7%

   Reported 2025 results, cash runway and key 2026 clinical milestones.

2. Mar 16

   Inducement grant

   24h Move

   -1.9%

   Inducement stock option grant to a new employee under plan.

3. Feb 24

   Conference presentation

   24h Move

   +1.4%

   Announcement of participation at TD Cowen healthcare conference.

4. Feb 17

   KOL event

   24h Move

   +3.1%

   Planned KOL event focused on vonaprument and ARCHER II trial.

5. Jan 16

   Inducement grants

   24h Move

   +1.5%

   Inducement equity awards to two new non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuroinflammatory diseases

1 terms

neuroinflammatory diseases medical

"targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million"

Neuroinflammatory diseases are conditions in which the body's immune response causes inflammation in the brain or spinal cord, damaging nerve cells and disrupting normal brain signaling. For investors, these illnesses matter because they shape demand for new drugs, diagnostics, and long-term care services, affect the size and risk of clinical trials, and influence regulatory and reimbursement outcomes—think of a neighborhood fire that changes the value and repair costs of every building on the block.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to millions of patients to help them live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Annexon (ANNX) present at the Needham Virtual Healthcare Conference?

Annexon will present on April 15, 2026 at 11:45 a.m. ET. According to Annexon, Douglas Love, CEO, will deliver the presentation and participate in related investor outreach during the virtual event.

How can investors watch Annexon's (ANNX) presentation on April 15, 2026?

Investors can access a live webcast via the company's Investors "Events & Presentations" page. According to Annexon, the webcast link will be available on the Annexon investor website for live viewing.

Will Annexon (ANNX) provide a replay of the Needham conference presentation?

Yes. According to Annexon, a replay of the webcast will be archived on the company's website for 30 days following the presentation, allowing investors to view the talk after the live event.

Who from Annexon (ANNX) is presenting at the Needham conference on April 15, 2026?

Douglas Love, Esq., president and chief executive officer of Annexon, will present. According to Annexon, he will discuss the company's platform and investor-relevant updates during the scheduled virtual session.

Where is the Annexon (ANNX) webcast hosted and how long will it remain available?

The webcast is hosted on Annexon's investor website under "Events & Presentations" and will remain archived for 30 days post-event. According to Annexon, the replay will be accessible there for that 30-day period.